Development of therapeutic fusion inhibitor peptides for Measles encephalitis
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
批准号:
8248767
负责人:
Matteo Porotto
金额:
$18.99万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2013-03-31
关键词:
AcuteAmino Acid SubstitutionAnimal ModelAntiviral AgentsBindingBiological AvailabilityBlood - brain barrier anatomyCell membraneCentral Nervous System InfectionsCessation of lifeChikungunya virusChildChimeric ProteinsCholesterolCommunicable DiseasesComplementComplexDevelopmentDiseaseDominant-Negative MutationEffectivenessEncephalitisEncephalomyelitisEntropyF Protein Measles VirusHIVHendra VirusHumanImmunocompromised HostIn VitroInfectionInfectious EncephalitisKineticsLeadMeaslesMeasles virusMediatingMembraneMembrane FusionModelingMusNew AgentsPara-Influenza Virus Type 3ParamyxovirusPenetrationPeptidesPopulationProgressive DiseaseProtein RegionProteinsSLAM proteinSeriesSiteStructureSubacute Sclerosing PanencephalitisTestingTherapeuticTransgenic MiceTransgenic OrganismsTransmembrane DomainVaccinationVaccinesViralViral EncephalitisViral Fusion ProteinsVirusWest Nile virusbaseenthalpyfundamental researchhuman trophoblast leucocyte common antigenin vivoinhibitor/antagonistmouse modelpathogenpre-clinicalpreventprotein aminoacid sequencereceptorresearch studytherapeutic development
中文摘要
描述(由申请人提供):病毒性脑炎正在成为一个令人担忧的原因,最近出现了一系列严重CNS感染的新病原体,包括几种可导致人类致命脑炎的人畜共患病毒。一种长期以来一直是人类病原体的病毒仍然排在榜首:麻疹。麻疹病毒(MV)在世界范围内引起疾病,尽管努力通过疫苗根除,主要是因为它很容易在人与人之间传播。虽然这种疾病通常是自限性的,但几种严重的并发症涉及CNS并导致后遗症或死亡。这些中枢神经系统表现可在感染后早期出现,如急性脑脊髓炎,或在感染后数年出现,如亚急性硬化性全脑炎病毒持续存在。MV引起的CNS疾病的第三种形式,进行性感染性脑炎,发生在麻疹感染后1至6个月,并且在免疫功能低下患者的增加中是有问题的。麻疹的急性或持续性CNS并发症没有特异性治疗。我们建议将我们的基础研究结果应用于麻疹CNS感染的新的抗病毒策略的开发。该提议是基于我们最近的发现,即胆固醇基团与肽融合抑制剂的连接产生3个主要优点:(1)增加的效力,(2)肽与病毒在融合激活位点的定位,和(3)CNS渗透。我们表明胆固醇标记的肽在体外对麻疹病毒高度有效,并且我们提出在表达MV受体人CD 150(SLAM)的转基因鼠脑炎模型中评估它们治疗CNS的麻疹感染的潜力。通过将序列优化与胆固醇标记相结合,我们提出开发在体外抑制MV的高效肽融合抗病毒药物,并在MV脑炎的相关动物模型中测试其治疗潜力。我们将通过以下方式对我们的主要候选治疗药物进行临床前开发:目标1。使用(a)生物物理分析指导的序列优化和(B)膜靶向,引导靶向质膜的MV融合抑制剂肽的优化。目标2.融合抑制剂在转基因小鼠模型中保护免受野生型MV诱导的麻疹脑炎的有效性。我们将评估(a)靶向肽的生物利用度,和(B)在CD 150(SLAM)转基因小鼠模型中的激发实验中的功效。因此,我们将获得有效性的原理证明,从而使我们能够选择具有最大体内潜力的肽进行改进。
英文摘要
DESCRIPTION (provided by applicant): Viral encephalitis is rising as a cause for alarm, with the recent emergence of a series of new agents of serious CNS infection, including several zoonotic viruses that cause lethal encephalitis in humans. One virus that has long been a human pathogen remains at the top of the list: measles. Measles virus (MV) causes disease worldwide despite efforts towards eradication by vaccine, largely because it is spread so readily between people. While the disease is generally self-limited, several serious complications involve the CNS and lead to sequelae or death. These CNS manifestations may occur early after infection, in the case of acute encephalomyelitis, or years after infection, as a result of viral persistence in subacute sclerosing panencephalitis. The third form of MV-induced CNS disease, progressive infectious encephalitis, occurs 1 to 6 months following measles infection, and is problematic in an increasing population of immunocompromised patients. There is no specific therapy for acute or persistent CNS complications of measles. We propose to apply the results of our fundamental research to the development of a new antiviral strategy for measles CNS infection. The proposal is based on our recent discovery that attachment of a cholesterol group to a peptide fusion inhibitor yields 3 major advantages: (1) increased potency, (2) localization of the peptide with the virus at the site of fusion activation, and (3) CNS penetration. We showed that cholesterol- tagged peptides are highly effective against measles virus in vitro, and we propose to assess their potential to treat measles infection of the CNS in a transgenic murine encephalitis model expressing the MV receptor human CD150 (SLAM). By combining sequence optimization with cholesterol tagging, we propose to develop highly effective peptide fusion antivirals that inhibit MV in vitro, and to test their therapeutic potential in a relevant animal model of MV encephalitis. We will pursue preclinical development of our lead therapeutic candidate by: Aim 1. Lead optimization of MV fusion inhibitor peptides targeted to the plasma membrane, using (a) biophysical analysis-guided sequence optimization, and (b) membrane targeting. Aim 2. Effectiveness of the fusion inhibitors to protect from measles encephalitis induced by wild type MV in a transgenic murine model. We will assess (a) bioavailability of the targeted peptides, and (b) efficacy in challenge experiments in a CD150(SLAM) transgenic mouse model. We will thereby obtain proof of principle for efficacy, allowing us to select peptides for advancement that have the most in vivo potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Design of fusion inhibitors to block measles host-to-host infection
-
批准号:10753711
-
项目类别:
-
资助金额:$73.69万
-
财政年份:2023
-
负责人:Matteo Porotto
-
依托单位:
Design of fusion inhibitors to block measles host-to-host infection
-
批准号:10457081
-
项目类别:
-
资助金额:$56.12万
-
财政年份:2021
-
负责人:Matteo Porotto
-
依托单位:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
-
批准号:10457959
-
项目类别:
-
资助金额:$71.66万
-
财政年份:2021
-
负责人:Matteo Porotto
-
依托单位:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
-
批准号:10668973
-
项目类别:
-
资助金额:$71.41万
-
财政年份:2021
-
负责人:Matteo Porotto
-
依托单位:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
-
批准号:10237600
-
项目类别:
-
资助金额:$75.02万
-
财政年份:2021
-
负责人:Matteo Porotto
-
依托单位:
Small molecules to block measles spreading in the central nervous system
-
批准号:9986209
-
项目类别:
-
资助金额:$49.26万
-
财政年份:2019
-
负责人:Matteo Porotto
-
依托单位:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
-
批准号:10414909
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:Matteo Porotto
-
依托单位:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
-
批准号:10178126
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:Matteo Porotto
-
依托单位:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
-
批准号:9973101
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:Matteo Porotto
-
依托单位:
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
-
批准号:9441694
-
项目类别:
-
资助金额:$64.49万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
-
批准号:9431045
-
项目类别:
-
资助金额:$61.08万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
-
批准号:9888329
-
项目类别:
-
资助金额:$65.98万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
-
批准号:9241965
-
项目类别:
-
资助金额:$68.48万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
-
批准号:9232064
-
项目类别:
-
资助金额:$60.67万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
-
批准号:9119228
-
项目类别:
-
资助金额:$70.45万
-
财政年份:2016
-
负责人:Matteo Porotto
-
依托单位:
Mechanisms of measles virus CNS adaptation
-
批准号:9419291
-
项目类别:
-
资助金额:$37.36万
-
财政年份:2015
-
负责人:Matteo Porotto
-
依托单位:
Mechanisms of measles virus CNS adaptation
-
批准号:9270221
-
项目类别:
-
资助金额:$37.36万
-
财政年份:2015
-
负责人:Matteo Porotto
-
依托单位:
Measles infection blockage by intranasal delivery of F targeting peptides
-
批准号:8914712
-
项目类别:
-
资助金额:$55.77万
-
财政年份:2014
-
负责人:Matteo Porotto
-
依托单位:
Active and arrested paramyxovirus fusion machinery visualized by cryo-electron to
-
批准号:8540333
-
项目类别:
-
资助金额:$22.1万
-
财政年份:2012
-
负责人:Matteo Porotto
-
依托单位:
Development of antivirals for newly emerging pathogens Ebola and Marburg.
-
批准号:8242461
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2012
-
负责人:Matteo Porotto
-
依托单位:
海外基金